MEDIMMUNE, ASTRAZENECA’S BIOLOGICS ARM, AND NGM BIOPHARMACEUTICALS ANNOUNCE AGREEMENT TO DISCOVER AND DEVELOP THERAPIES FOR DIABETES AND OBESITY

Nyheten uppdaterades 2013-06-17 8:19

AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the treatment type 2 diabetes and obesity.

EECs represent less than 1% of all gastrointestinal (GI) cells,…

Källa: Mynewsdesk news release

Lämna gärna en kommentar